Scancell (LON:SCLP) Posts Quarterly Earnings Results

Scancell (LON:SCLP) issued its quarterly earnings data on Friday. The company reported GBX (1.73) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Scancell had a negative net margin of 116.98% and a positive return on equity of 90.29%.

Scancell Trading Down 1.1%

Shares of SCLP stock opened at GBX 9.30 on Friday. The firm has a 50-day moving average price of GBX 9.67 and a 200 day moving average price of GBX 13.94. Scancell has a twelve month low of GBX 9.10 and a twelve month high of GBX 29.50. The company has a market capitalization of £126.17 million, a price-to-earnings ratio of -16.91 and a beta of 0.69. The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.